Amneal Pharmaceuticals (AMRX) announced that the FDA has approved the company’s epinephrine injection USP, 1 mg/mL, in single-dose vials and 1 mg/mL multi-dose vials. This medicine is a critical therapy utilized by hospitals, emergency departments and other acute care facilities for patient care.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMRX:
- Amneal Pharmaceuticals initiated with an Overweight at Barclays
- Amneal Pharmaceuticals announces results from Phase 4 ELEVATE-PD
- Amneal receives U.S. FDA approval for albuterol sulfate inhalation aerosol
- Closing Bell Movers: MongoDB jumps 22% on earnings beat and raise
- Amneal announces FDA approval of cyclosporine ophthalmic emulsion 0.05%